Table 5 CBD group correlation analyses: percent change of menstrual symptoms and suppository use during month 1

	Average % change: (baseline to month 1)	Correlations: % change vs # CBD suppositories
	Mean ± SD	r	p	n
Verbal multidimensional scoring system (VMS) assessment of dysmenorrhea
Effect on work	−15.13% ±35.69%	−0.149	0.236	65
Required analgesics	−15.10% ±39.59%	−0.290	0.020	64
Systemic symptoms	−15.34% ±35.08%	−0.282	0.025	63
Retrospective symptom scale (RSS) of dysmenorrhea
Frequency	−10.94% ±27.91%	−0.367	0.003	63
Severity	−15.88% ±26.06%	−0.371	0.003	63
# Hours spent in bed	−9.96% ±66.69%	−0.314	0.014	61
# Analgesic pills	−37.59% ±51.21%	−0.221	0.115	61
Menstrual symptom questionnaire (MSQ)
Congestive symptoms	−7.27% ±14.01%	−0.361	0.003	66
Menstrual distress questionnaire (MDQ)
Premenstrual symptoms
Behavioral changes^a	−10.59% ±50.16%	−0.235	0.061	64
Autonomic reactions	−16.77% ±100.32%	−0.131	0.317	60
Symptoms during menstruation
Pain	−12.46% ±24.93%	−0.331	0.008	63
Concentration	12.58% ±129.76%	−0.110	0.403	60
Behavioral changes	−3.41% ±114.79%	0.068	0.599	62
Autonomic reactions	−10.58% ±94.24%	−0.148	0.280	55
Water retention	−6.30% ±46.34%	−0.306	0.015	63
Negative affect	−12.46% ±45.12%	−0.361	0.004	62

Bold numbers are significant at p ≤ 0.050; italicized numbers are trending towards significance at p ≤ 0.100.
Note: Correlation analyses were only performed for menstrual variables with significant group*time interactions from the linear mixed model analyses.
^aAn exploratory correlation of a subset of participants who reported suppository use during the premenstrual phase (n = 37) was significant r = −0.336, p = 0.042.

Quick links

Search